Phase III Will Be Real Test For vTv's Resurrected Alzheimer's Drug

Phase IIb data for vTv Therapeutics' lead product azeliragon have demonstrated an effect on cognitive deterioration in mild Alzheimer’s disease patients – but is this evidence enough to get the small biotech back on track after it lost Pfizer Inc. as a partner for the drug in 2012?